Fig. 1From: First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case reportThe patient’s treatment history and chronological imaging follow-up results. A CT of the abdomen before alectinib treatment (The red arrow indicates new metastases in the liver). B CT of the abdomen after 3 months of alectinib treatment (The red arrow indicates that the metastases in the liver were reduced). C CT of the abdomen before treatment of ensartinib treatment (The red arrow shows that the multiple liver lesions were significantly increased and enlarged). D CT of the abdomen after 20 days of ensartinib treatment (The red arrows show that the multiple liver lesions were significantly reduced). E Brain MRI after 3 months of ensartinib treatmentBack to article page